STRO
NASDAQSutro Biopharma Inc.
Price$10.91-12.73 (-53.83%)
2026-07-162026-10-16
News · 26 weeks34+100%
2026-04-192026-10-11
Mix990d
- Other3(33%)
- Analyst2(22%)
- SEC Filings2(22%)
- Insider1(11%)
- Leadership1(11%)
Latest news
25 items- PRSutro Biopharma Announces Participation at the 17th Annual World ADC ConferenceSOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026. "Sutro's presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical safety and pharmacokinetic profile of STRO-004 to new preclinical insights on STRO-006 and our first wholly-owned dual-payload ADC, STRO-227," said Hans-Peter Gerber, Ph.D., Sutro's Chief Scientific Of
- ANALYSTWells Fargo resumed coverage on Sutro Biopharma with a new price targetWells Fargo resumed coverage of Sutro Biopharma with a rating of Overweight and set a new price target of $49.00
- PRSutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business DevelopmentSOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026. Mr. Donigian brings more than 20 years of biotechnology industry experience, with a background in business development, corporate strategy, and alliance management. He has a demonstrated history of executing high-value oncology partnerships, including in the ADC space, with an aggregate deal value of over $2 billion. "We are thrilled
- INSIDERCHIEF SCIENTIFIC OFFICER Gerber Hans-Peter converted options into 3,750 shares and covered exercise/tax liability with 1,345 shares, increasing direct ownership by 24% to 12,367 units (SEC Form 4) to satisfy tax liability4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.SCHEDULE 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- SECSEC Form 10-Q filed by Sutro Biopharma Inc.10-Q - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- SECSutro Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- PRSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study– Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Second dual-payload iADC program from Sutro’s platform under Astellas collaboration expected to enter the clinic in the second half of 2026 – – Strong balance sheet with $164.3 million in cash, cash e
- ANALYSTStifel initiated coverage on Sutro Biopharma with a new price targetStifel initiated coverage of Sutro Biopharma with a rating of Buy and set a new price target of $48.00
- ANALYSTTruist resumed coverage on Sutro Biopharma with a new price targetTruist resumed coverage of Sutro Biopharma with a rating of Buy and set a new price target of $50.00
- INSIDERSEC Form 4 filed by Director Wigginton Jon Marc4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Petree Daniel H4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Panek James P4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Lobacki Joseph M4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Jagpal Sukhi4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Hunter Heidi4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Dybbs Michael4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Matsui Connie4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- SECSEC Form 8-K filed by Sutro Biopharma Inc.8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- INSIDERCFO Chow Gregory K. converted options into 2,500 shares, increasing direct ownership by 112% to 4,725 units (SEC Form 4) (withholding obligation)4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- ANALYSTBarclays initiated coverage on Sutro Biopharma with a new price targetBarclays initiated coverage of Sutro Biopharma with a rating of Overweight and set a new price target of $56.00
- SECSEC Form SCHEDULE 13G filed by Sutro Biopharma Inc.SCHEDULE 13G - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.SCHEDULE 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- ANALYSTSutro Biopharma upgraded by Wedbush with a new price targetWedbush upgraded Sutro Biopharma from Neutral to Outperform and set a new price target of $60.00
- SECSEC Form 10-Q filed by Sutro Biopharma Inc.10-Q - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
STRO FAQ
7 questionsWhat does Sutro Biopharma Inc. do?
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and...Where does STRO stock trade?
Sutro Biopharma Inc. (STRO) is listed on NASDAQ.What sector and industry is STRO in?
Sutro Biopharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Sutro Biopharma Inc. go public?
Sutro Biopharma Inc. (STRO) completed its IPO in 2018.What are analysts saying about STRO?
Sutro Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $4900.00 price target on 2026-09-30. Recent price targets range from $2700.00 to $4900.00.What companies are similar to STRO?
Notable peers in the same industry include CUE (Cue Biopharma Inc.), GTBP (GT Biopharma Inc.), MTNB (Matinas Biopharma Holdings Inc.). Compare STRO side-by-side with any of them on Quantisnow.How can I track STRO on Quantisnow?
Quantisnow aggregates Sutro Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STRO to receive live email and push alerts on every new disclosure.